Your Web Site
Calando Patent Issued for Active Ingredient of Lead siRNA Drug Candidate, CALAA-01
The patent contains claims directed to inhibitory nucleic acid sequences targeting the Ribonucleotide Reductase Subunit 2 ("R2") gene, as well as pharmaceutical compositions and methods for inhibiting tumor growth utilizing the...
